Interpace Biosciences Inc (IDXG)
1.48
+0.10
(+7.25%)
USD |
OTCM |
May 24, 16:00
Interpace Biosciences Net Income (Quarterly): 0.468M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.468M |
| December 31, 2023 | 0.89M |
| June 30, 2023 | 0.175M |
| March 31, 2023 | 0.351M |
| December 31, 2022 | -1.564M |
| September 30, 2022 | -14.21M |
| June 30, 2022 | -3.939M |
| March 31, 2022 | -2.247M |
| December 31, 2021 | -3.729M |
| September 30, 2021 | -3.561M |
| June 30, 2021 | -3.446M |
| March 31, 2021 | -4.207M |
| December 31, 2020 | -8.143M |
| September 30, 2020 | -6.234M |
| June 30, 2020 | -5.58M |
| March 31, 2020 | -6.494M |
| December 31, 2019 | -10.66M |
| September 30, 2019 | -7.446M |
| June 30, 2019 | -5.304M |
| March 31, 2019 | -3.326M |
| December 31, 2018 | -4.551M |
| September 30, 2018 | -3.042M |
| June 30, 2018 | -1.917M |
| March 31, 2018 | -3.193M |
| December 31, 2017 | -5.008M |
| Date | Value |
|---|---|
| September 30, 2017 | -3.316M |
| June 30, 2017 | -6.306M |
| March 31, 2017 | 2.414M |
| December 31, 2016 | 6.281M |
| September 30, 2016 | -7.493M |
| June 30, 2016 | -2.334M |
| March 31, 2016 | -4.786M |
| December 31, 2015 | 4.385M |
| September 30, 2015 | -4.895M |
| June 30, 2015 | -6.978M |
| March 31, 2015 | -3.868M |
| December 31, 2014 | -7.468M |
| September 30, 2014 | -4.336M |
| June 30, 2014 | -2.658M |
| March 31, 2014 | -1.612M |
| December 31, 2013 | -3.666M |
| September 30, 2013 | -2.141M |
| June 30, 2013 | -0.883M |
| March 31, 2013 | 2.126M |
| December 31, 2012 | -23.80M |
| September 30, 2012 | -1.019M |
| June 30, 2012 | -0.439M |
| March 31, 2012 | -0.272M |
| December 31, 2011 | -10.27M |
| September 30, 2011 | -0.202M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-14.21M
Minimum
Sep 2022
0.89M
Maximum
Dec 2023
-4.467M
Average
-3.939M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Fonar Corp | 1.872M |
| XWELL Inc | -2.512M |
| ProPhase Labs Inc | -6.265M |
| Applied DNA Sciences Inc | -4.470M |
| Veracyte Inc | -1.864M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 9.399M |
| EPS Diluted (Quarterly) | 0.11 |
| Enterprise Value | 12.51M |
| Gross Profit Margin (Quarterly) | 59.10% |
| Profit Margin (Quarterly) | 4.56% |
| Earnings Yield | 29.05% |
| Operating Earnings Yield | 57.49% |
| Normalized Earnings Yield | 33.89 |